form-424b3_072602
PROSPECTUS

                             MEDIX RESOURCES, INC.

                        496,250 Shares of Common Stock

     The shareholders of Medix Resources,  Inc. named herein will have the right
to offer and sell up to an aggregate of 496,250 shares of our common stock under
this Prospectus.

     Medix will not receive  directly any of the proceeds from the sale of these
shares by the selling shareholders.  However, Medix will receive the proceeds of
the  exercise  of the options  and  warrants  to purchase  the shares to be sold
hereunder. Medix will pay the expenses of registration of these shares.

     The common stock is traded on the American  Stock Exchange under the symbol
"MXR".  On July 24, 2002,  the closing price of the common stock was reported as
$0.31.

     Medix has  available to it an equity line of credit that permits it to draw
funds for its  operations,  from time to time,  and issue  shares of its  common
stock to the  providers  of such  facility in  connection  with such draws.  The
shares  issued  are  registered  so that  they  can be sold to the  public  upon
issuance. Currently, 4,796,763 shares are registered for sale by the equity line
of  credit   providers  in  connection  with  future  draws.  See  "Equity  Line
Financing."

     The  securities  offered  hereby  involve a high degree of risk.  See "RISK
FACTORS"  beginning  on page 3 for certain  risks that should be  considered  by
prospective purchasers of the securities offered hereby.

     Neither the  Securities and Exchange  Commission  nor any state  securities
commission  has approved or  disapproved of the securities or determined if this
prospectus  is truthful or  complete.  Any  representation  to the contrary is a
criminal offense.


                  The date of this Prospectus is July 25, 2002



                         Supplements to this Prospectus

     A copy of each  Form  10-Q and  Form 8-K that is filed by Medix  Resources,
Inc.  with  the  Securities  and  Exchange  Commission  after  the  date of this
Prospectus  shall be deemed to be a Supplement to this  Prospectus,  and must be
physically delivered with this Prospectus to a prospective  purchaser,  together
with a copy of the  company's  2001 Form  10-K,  as  amended.  Unless  otherwise
notified, this Prospectus,  as amended or supplemented from time to time, may be
used for sales by the persons  named herein until April 30, 2003,  at which time
the audited financial  statements  incorporated  herein by reference will become
stale pursuant to Section 10(a)(3) of the Securities Act of 1933, as amended.

     No  dealer,  salesman  or  other  person  has been  authorized  to give any
information or to make any  representation  not contained in or  incorporated by
reference  in this  Prospectus  and,  if  given  or made,  such  information  or
representation  must not be relied  upon as having  been  authorized  by us, the
selling shareholders or any other person. This Prospectus does not constitute an
offer to sell or a solicitation of an offer to buy any of the securities offered
hereby in any  jurisdiction to any person to whom it is unlawful to make such an
offer in such jurisdiction. Neither the delivery of this Prospectus nor any sale
made hereunder shall, under any  circumstances,  create any implication that the
information  herein is correct as of any time  subsequent  to the date hereof or
that there has been no change in our affairs since such date.

                                     __________________

                                     TABLE OF CONTENTS
                                     __________________


SUMMARY

RISK FACTORS

FORWARD-LOOKING STATEMENTS

THE COMPANY

EQUITY LINE FINANCING

USE OF PROCEEDS

SELLING SHAREHOLDERS

DESCRIPTION OF SECURITIES

PLAN OF DISTRIBUTION

INDEMNIFICATION OF OFFICERS AND DIRECTORS

AVAILABLE INFORMATION

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

LEGAL MATTERS

EXPERTS



                                 SUMMARY

     This Prospectus covers the offering and sale of up to 496,250 shares of our
common  stock to the public by certain  selling  shareholders  listed  under the
heading "Selling  Shareholders" further back in this Prospectus.  As of July 24,
2002,  we  had  62,923,624   shares  of  our  common  stock   outstanding,   and
approximately  28,845,337  shares were issuable upon the exercise of outstanding
options,  warrants or other rights, and the conversion of outstanding  preferred
stock.

     We are developing  software products for Internet-based  communications and
information  management by medical  service  providers.  We have no revenue from
operations and are funding the development of our software  products through the
sales of our  securities.  We have  granted a  security  interest  in all of our
intellectual  property  assets to secure a  financing.  See "The  Company-Recent
Developments" and "Risk Factors."

     Because  of our  continuing  losses,  and the lack of a  certain  source of
capital  to  fund  our  development  of  software   products,   our  independent
accountants  included a "going  concern"  exception in their audit report on our
audited  financial  statements for the year 2001. The "going concern"  exception
signifies  that  significant  questions  exist  about our ability to continue in
business. See "Risk Factors."

     Currently, we are funding our development and deployment activities through
an equity line of credit financing, which is not an assured source of funds. The
equity line of credit is provided by Cornell Capital Partners,  L.P. and Duchess
Private  Equities  Fund,  L.P.  (the  "providers"),  which  jointly  provide the
facility under a single agreement.  The agreement provides that we may draw down
up to $10,000,000 over its two-year term,  ending June 12, 2003,  subject to the
conditions  for the draws being  satisfied,  which can not be assured.  We issue
shares of our common stock to the providers of such facility in connection  with
such draws.  The shares  issued are  registered  so that they can be sold to the
public  immediately  upon issuance.  We have made 17 draws on the equity line of
credit since August of 2001. As of July 24, 2002, we had received  $2,681,099 in
advances,  from which offering expenses of $198,511 were paid, and had issued to
the providers 4,703,237 shares of our common stock relating to the advances.  An
additional  542,847  shares have been issued to  affiliates  of the providers as
fees for arranging the equity line  facility.  Currently,  4,796,763  shares are
registered for sale by the providers in connection with future draws. The shares
issued  pursuant to the equity line advances to date have been priced from $0.41
to $0.77 per share. See "Risk Factors" and "Equity Line Financing."

     Our principal  executive office is located at 420 Lexington  Avenue,  Suite
1830,  New York,  NY 10170,  and its  telephone  number is (212)  697-2509.  Our
principal  administrative  office  is at 7100  East  Belleview  Ave.,  Greenwood
Village, CO 80111, and its telephone number is (303) 741-2045.


                               RISK FACTORS

   An investment in our common stock:

     o    has a high degree of risk;
     o    is highly speculative;
     o    should only be  considered by those persons or entities who can afford
          to lose their entire investment.

     In addition to the other  information  contained  in this  Prospectus,  the
following risk factors should be carefully considered in evaluating our business
and an investment in our shares.  The order in which the following  risk factors
are presented does not indicate the relative magnitude of the risks described.

     Our  continuing   losses   endanger  our  viability  and  have  caused  our
accountants to issue a "going concern" exception in their annual audit report.

     We reported net losses of ($10,636,000),  ($5,415,000) and ($4,847,000) for
the years ended December 31, 2001, 2000 and 1999,  respectively,  and a net loss
of ($1,677,000) for the quarter ending March 31, 2002. At March 31, 2002, we had
an  accumulated  deficit  of  ($35,737,000)  and a negative  working  capital of
($1,396,000).  Our  Cymedix(R)products  are still in the testing and  deployment
stage and have not generated any significant revenue to date. We are funding our
operations through the sale of our securities.  Our independent accountants have
included a "going concern"  exception in their audit reports on our audited 2000
and 2001  financial  statements.  See our Form 10-K, as amended,  for the fiscal
year ended December 31, 2001.

     Our need for  additional  financing is acute and failure to obtain it could
lead to the financial failure of our company.

     We expect to continue to experience  losses,  in the near term,  until such
time  as our  Cymedix(R)software  products  can be  successfully  deployed  with
customers  and  produce  revenue.  The  continuing  development,  marketing  and
deployment  of the  Cymedix  software  products  will depend upon our ability to
obtain additional  financing.  Our Cymedix(R)  products are still in the testing
and deployment stage and have not generated any significant  revenue to date. We
are funding our operations  through the sale of our securities.  There can be no
assurance that  additional  investments or financings will be available to us as
needed to support the development and deployment of Cymedix products. Failure to
obtain  such  capital  on  a  timely   basis  could  result  in  lost   business
opportunities,  the sale of the Cymedix  business at a  distressed  price or the
financial failure of our company. See "The Company-Recent Developments."

     Medix has frequent  cash flow problems that often cause us to be delinquent
in making payments to our vendors and other creditors, which may cause damage to
our  business  relationships  and cause us to incur  additional  expenses in the
payment of late charges and penalties.

     During 2001, from time to time, its lack of cash flow caused Medix to delay
payment of its obligations as they came due in the ordinary of its business.  In
some cases,  Medix was delinquent in making payments by the legally required due
dates. At its four office  locations,  Medix had 48 monthly  payments due in the
aggregate during 2001. 31 of those payments were late. 23 of those payments were
paid within 30 days of their due date,  and 8 of those  payments were between 31
and 60 days late. All payments plus any required  penalties were ultimately paid
in full during  2001.  Medix had 33 Federal  withholding  and other  payment due
dates. Of those, 17 due dates were missed.  The resulting  delinquencies  ranged
from 1 to 58 days,  before  the  required  payments  were  made.  Medix pays the
resulting penalties as they are billed. Medix had state withholding  obligations
in five states,  Colorado,  California,  Georgia, New Jersey and New York. Medix
was late in making 45 of 97  withholding  payments  in those  five  states.  The
length of these  delinquencies  ranged  from 3 to 60 days,  before the  required
payments were made. Medix pays the resulting penalties as they are billed. Medix
was late in making its deposits of its employees' 401(k)  contributions 21 of 26
times during 2001. The length of these delinquencies  ranged from 10 to 60 days,
All of the above late payments were made before the end of 2001.

     We have  granted a security  interest in all of our  intellectual  property
assets to secure a financing,  which means if we default in our  obligations  to
the lender, we may loss these assets in the foreclosure process.

     The use of secured borrowings increases the risk of loss of the assets used
to secure  the  borrowing.  If an event of  default  occurs  under the  security
agreement, the lender will be able to foreclose on the assets used to secure the
borrowing  and sell those  assets to the  highest  bidder.  In  addition,  it is
generally believed that foreclosure sales, which are "distress sales",  will not
maximize  the  proceeds  that are paid for the assets  being  sold.  The loan we
entered  into is  secured  by the grant of a security  interest  in all  Medix's
intellectual property,  including its patent,  copyrights and trademarks.  While
Medix can cure a payment  default by the forced  conversion of the loan into its
common  stock,  a  bankruptcy  or similar  event of  default  will  trigger  the
foreclosure  provision  of  the  security  agreement.  See  "The  Company-Recent
Developments."

     We are a development  stage company,  which means our products and services
have not yet proved themselves  commercially  viable and therefore our future is
uncertain.

     o    We develop software for Internet-based  communications and information
          management for medical  service  providers,  through our  wholly-owned
          subsidiary, Cymedix Lynx Corporation. Our Cymedix(R)products are still
          in the  testing  and  deployment  stage  and  have not  generated  any
          significant revenue to date. We are funding our operations through the
          sale of our securities. Our ability to continue to sell our securities
          can not be assured.

     o    We are  still  in the  process  of  gaining  experience  in  marketing
          software  products,  providing  software support services,  evaluating
          demand for  products,  financing a software  business and dealing with
          government  regulation  of  software  products.  While we are  putting
          together  a team  of  experienced  executives,  they  have  come  from
          different  backgrounds  and  may  require  some  time  to  develop  an
          efficient  operating  structure and corporate culture for our company.
          We believe our  structure  of multiple  offices  serves our  customers
          well,  but it does  present an  additional  challenge  in building our
          corporate culture and operating structure.

     We rely on healthcare professionals for the quality of the information that
is transmitted through our interconnectivity systems, and we may not be paid for
our  services  by  third-party  payors  if that  quality  does not meet  certain
standards.

     The  success of our  products  and  services in  generating  revenue may be
subject to the quality and completeness of the data that is generated and stored
by  the  physician  or  other  healthcare  professional  and  entered  into  our
interconnectivity  systems,  including  the  failure  to  input  appropriate  or
accurate information. Failure or unwillingness by the healthcare professional to
accommodate the required information quality may result in the payor refusing to
pay Medix for its services.

     Our market is rapidly  changing and the  introduction of software  services
and products into that market has been slow,  which may cause us to be unable to
develop a profitable market for our services and products.

     o    As a developer of software products, we will be required to anticipate
          and  adapt  to  evolving  industry  standards  and  new  technological
          developments. The market for our software products is characterized by
          continued  and  rapid  technological  advances  in both  hardware  and
          software development,  requiring ongoing expenditures for research and
          development,  and timely introduction of new products and enhancements
          to existing  products.  The  establishment  of  standards is largely a
          function of user acceptance.  Therefore, such standards are subject to
          change.  Our  future  success,  if any,  will  depend in part upon our
          ability to  enhance  existing  products,  to  respond  effectively  to
          technology  changes,  and to introduce  new products and  technologies
          that are  functional and meet the evolving needs of our clients in the
          healthcare information systems market.

     o    The introduction of software  products in our market has been slow due
          to the large number of small practitioners who are resistant to change
          and the costs  associated  with  change,  particularly  in a period of
          rising  pressure  to  reduce  costs in the  market.  We are  currently
          devoting  significant  resources  toward the  development of products.
          There  can be no  assurance  that we will  successfully  complete  the
          development  of these products in a timely fashion or that our current
          or  future   products  will  satisfy  the  needs  of  the   healthcare
          information  systems market.  Further,  there can be no assurance that
          products or technologies developed by others will not adversely affect
          our  competitive  position  or render  our  products  or  technologies
          noncompetitive or obsolete.

     As a provider of medical  software  products  and  services,  we may become
liable for product  liability  claims  beyond the levels of our  insurance  that
could have a materially adverse impact on our financial condition.

     Certain of our products provide applications that relate to patient medical
histories and treatment plans. Any failure by our products to provide  accurate,
secure and timely  information  could result in product liability claims against
us by our clients or their affiliates or patients. We maintain insurance that we
believe  currently is adequate to protect against claims associated with the use
of our products, but there can be no assurance that our insurance coverage would
adequately  cover any claim asserted against us. The limits of that coverage are
$2,000,000 in the aggregate and $1,000,000 per  occurrence.  A successful  claim
brought  against us in excess of our  insurance  coverage  could have a material
adverse  effect on our results of operations,  financial  condition or business.
Even unsuccessful claims could result in the expenditure of funds in litigation,
as well as diversion of management time and resources.

     Our industry, the healthcare industry, continually experiences rapid change
and  uncertainty  that  could  result in issues  for our  business  planning  or
operations that could severely impact on our ability to become profitable.

     The healthcare and medical  services  industry in the United States is in a
period  of  rapid  change  and  uncertainty.  Governmental  programs  have  been
proposed,  and some adopted, from time to time, to reform various aspects of the
U.S.  healthcare  delivery system.  Some of these programs contain  proposals to
increase  government  involvement in healthcare,  lower  reimbursement rates and
otherwise change the operating environment for our customers.  Particularly, the
Health Insurance Portability and Accountability Act of 1996, and the regulations
that are being promulgated  thereunder,  are causing the healthcare  industry to
change its procedures and incur substantial cost in doing so. Although we expect
these  regulations  to have the  beneficial  effect of spurring  adoption of our
software  products we cannot  predict with any  certainty  what impact,  if any,
these and future healthcare reforms might have on our business.

     We rely on  intellectual  property  rights,  such as  patents,  copyrights,
trademarks and unprotected  propriety  technology in our business operations and
to  create  value in our  company,  however,  protecting  intellectual  property
frequently  requires  litigation  and close legal  monitoring  and may adversely
impact our ability to become profitable.

     o    Our  wholly-owned  subsidiary,  Cymedix  Lynx  Corporation,  has  been
          granted certain patent rights,  trademarks and copyrights  relating to
          its software business. These patents and copyrights have been assigned
          by our subsidiary to the parent company,  Medix. The patent rights and
          intellectual property legal issues for software programs,  such as the
          Cymedix(R)products,  are complex and currently evolving.  Since patent
          applications  are  secret  until  patents  are  issued,  in the United
          States,  or published,  in other countries,  we cannot be sure that we
          are the first to file any patent application.  In addition,  there can
          be no  assurance  that  competitors,  many of which  have far  greater
          resources  than we do, will not apply for and obtain patents that will
          interfere  with our ability to develop or market product ideas that we
          have originated. Further, the laws of certain foreign countries do not
          provide the  protection to  intellectual  property that is provided in
          the United  States,  and may limit our ability to market our  products
          overseas.  While we have no prospects  for  marketing or operations in
          foreign  countries at this time,  future  opportunities  for growth in
          foreign markets,  for that reason, may be limited.  We cannot give any
          assurance  that the scope of the rights that we have been  granted are
          broad enough to fully protect our Cymedix software from infringement.

     o    Litigation or regulatory  proceedings  may be necessary to protect our
          intellectual  property  rights,  such as the scope of our  patent.  In
          fact, the computer  software  industry in general is  characterized by
          substantial litigation. Such litigation and regulatory proceedings are
          very  expensive and could be a significant  drain on our resources and
          divert resources from product development.  There is no assurance that
          we will have the  financial  resources to defend our patent  rights or
          other intellectual property from infringement or claims of invalidity.
          We have been notified by a party that it believes our pharmacy product
          may infringe on patents that it holds. We have retained patent counsel
          who has  made a  preliminary  investigation  and  determined  that our
          product does not infringe on the identified  patents.  At this time no
          legal action has been instituted.

     o    We also rely upon unprotected  proprietary technology and no assurance
          can be given that others will not independently  develop substantially
          equivalent  proprietary  information  and techniques or otherwise gain
          access  to or  disclose  our  proprietary  technology  or  that we can
          meaningfully  protect  our  rights  in  such  unpatented   proprietary
          technology.  We will use our best efforts to protect such  information
          and techniques,  however,  no assurance can be given that such efforts
          will be successful.  The failure to protect our intellectual  property
          could cause us to lose  substantial  revenues and to fail to reach its
          financial potential over the long term.

     Because our business is highly  competitive and there are many  competitors
who are financially  stronger than we are, we are at risk of being  outperformed
in staffing,  marketing,  product development and customer services, which could
severely limit our ability to become profitable.

     o    eHealth   Services.   Competition  can  be  expected  to  emerge  from
          established  healthcare  information  vendors and  established  or new
          Internet  related vendors.  The most likely  competitors are companies
          with a focus on clinical  information  systems and enterprises with an
          Internet   commerce  or  electronic   network  focus.  Many  of  these
          competitors  will have  access to  substantially  greater  amounts  of
          capital  resources  than we have  access  to,  for  the  financing  of
          technical,  manufacturing  and marketing  efforts.  Frequently,  these
          competitors  will have  affiliations  with  major  medical  product or
          software  development  companies,  who may assist in the  financing of
          such competitor's product  development.  We will seek to raise capital
          to develop Cymedix  products in a timely manner,  however,  so long as
          our operations  remain  underfunded,  as they now are, we will be at a
          competitive disadvantage.

     o    Software Development Personnel.  The success of the development of our
          Cymedix  software  is  dependent  to a  significant  degree on our key
          management and technical  personnel.  We believe that our success will
          also depend upon our ability to attract,  motivate  and retain  highly
          skilled,  managerial,  sales and marketing,  and technical  personnel,
          including  software  programmers and systems architects skilled in the
          computer languages in which our Cymedix products operate.  Competition
          for such personnel in the software and information services industries
          is intense.  The loss of key  personnel,  or the  inability to hire or
          retain  qualified  personnel,  could have a material adverse effect on
          our results of operations, financial condition or business.

     We have  relied on the private  placement  exemption  to raise  substantial
amounts of capital,  and could suffer  substantial  losses if that exemption was
determined not to have been properly relied upon.

     We have raised  substantial  amounts of capital in private  placements from
time to  time.  The  securities  offered  in such  private  placements  were not
registered  with the SEC or any state agency in reliance  upon  exemptions  from
such registration  requirements.  Such exemptions are highly technical in nature
and if we  inadvertently  failed to comply with the  requirements of any of such
exemptive  provisions,  investors would have the right to rescind their purchase
of our  securities  or  sue  for  damages.  If one or  more  investors  were  to
successfully  seek such  rescission  or  institute  such suit,  Medix could face
severe financial  demands that could material and adversely affect our financial
position.

     The impact of shares of our common stock that may become available for sale
in the future may result in the market price of our stock being depressed.

     As of July 24, 2002, we had 62,923,624 shares of common stock  outstanding.
As of that date, approximately 28,845,337 shares were issuable upon the exercise
of  outstanding  options,  warrants  or  other  rights,  and the  conversion  of
preferred stock. Most of these shares will be immediately saleable upon exercise
or  conversion  under  registration  statements  we have filed with the SEC. The
exercise  prices of options,  warrants or other  rights to acquire  common stock
presently  outstanding range from $0.19 per share to $4.97 per share. During the
respective terms of the outstanding options, warrants, preferred stock and other
outstanding  derivative  securities,  the holders are given the  opportunity  to
profit from a rise in the market price of the common stock,  and the exercise of
any options, warrants or other rights may dilute the book value per share of the
common stock and put  downward  pressure on the price of the common  stock.  The
existence of the options,  conversion  rights,  or any outstanding  warrants may
adversely affect the terms on which we may obtain  additional  equity financing.
Moreover,  the holders of such securities are likely to exercise their rights to
acquire common stock at a time when we would otherwise be able to obtain capital
on terms  more  favorable  than  could  be  obtained  through  the  exercise  or
conversion of such securities.  See also the impact of our equity line of credit
financing discussed in the following paragraphs.

     Because of dilution to our common stock outstanding from our equity line of
credit, the market price of our stock may be depressed.

     o    In  connection  with our  equity  line of  credit  financing,  we have
          registered  9,500,000 shares with the SEC for sale by the providers of
          the financing, of which 4,796,763 shares remain available for issuance
          as of July 24, 2002. See "Equity Line Financing."

     o    The shares are issued to the equity line providers at a floating price
          based on a discount to market price of the common stock.  As a result,
          the lower the stock price around the time the equity line is drawn on,
          the more common shares the holder gets.

     o    To the extent that the equity line  providers  sells our common stock,
          the  market  price  of  the  common  stock  may  decrease  due  to the
          additional  shares in the market.  This could allow the  providers  to
          receive a greater  amount of the stock in future  draws on our  equity
          line of credit,  the sale of which  could  further  depress  the stock
          price.

     o    The significant  downward pressure on the price of our common stock as
          the equity line  providers  receive  common stock in  connection  with
          draws on our equity line of credit and then sell  material  amounts of
          the stock,  could  encourage  short sales,  which could place  further
          downward pressure on the price of our common stock.

     o    The issuance of the common stock in connection with our equity line of
          credit may result in substantial dilution to the common stock holdings
          of other holders of our common stock.

     o    Any  agreement  to sell,  or convert debt or equity  securities  into,
          common stock at a future date and at a price based on the then current
          market  price  will  provide an  incentive  to the  investor  or third
          parties  to sell the  common  stock  short to  decrease  the price and
          increase  the number of shares they may receive in a future  purchase,
          whether  directly from us or in the market.  Our equity line of credit
          is priced at a discount  to the  market  price at the time of a future
          draw.

     Because of dilution to our common  stock  outstanding  from the  conversion
feature of our $1,000,000  convertible  promissory note, the market price of our
stock may be depressed.

     o    The conversion price of our $1,000,000 promissory note may be equal to
          80% of the then-current market value of Medix common stock if Medix is
          unable  to  obtain  a  written   commitment  for   additional   equity
          investments of the aggregate of $4,000,000 by the close of business on
          September 30, 2002. As a result,  the lower the stock price around the
          time the  conversion is made, the more common shares the holder of the
          convertible   promissory   note  gets.   See  "The  Company  -  Recent
          Developments."

     o    The significant  downward pressure on the price of our common stock at
          the time the  conversion  price is set, could  encourage  short sales,
          which could place further downward pressure on the price of our common
          stock.

     o    The issuance of the common stock in connection with the conversion may
          result in  substantial  dilution to the common stock holdings of other
          holders of our common stock.

     o    Any  agreement  to sell,  or convert debt or equity  securities  into,
          common stock at a future date and at a price based on the then current
          market  price  will  provide an  incentive  to the  investor  or third
          parties  to sell the  common  stock  short to  decrease  the price and
          increase  the number of shares they may receive in a future  purchase,
          whether directly from us or in the market. The convertible  promissory
          note may be priced at a discount to market at the time the  conversion
          price is set, September 30, 2002.

     Because of market  volatility  in our stock price,  investors may find that
they have a loss position if emergency sales become necessary.

     Historically,   our  common  stock  has   experienced   significant   price
fluctuations. This has been caused by one or more of the following factors:

     o    unfavorable announcements or press releases relating to the technology
          sector;
     o    regulatory, legislative or other developments affecting our company or
          the health care industry generally;
     o    conversion of our  preferred  stock and  convertible  debt into common
          stock at conversion  rates based on current  market prices or below of
          our common stock and exercise of options and warrants at below current
          market prices;
     o    sales by those  financing our company through an equity line of credit
          or convertible  securities which have been registered with the SEC and
          may be sold into the public market immediately upon receipt; and
     o    market conditions specific to technology and internet  companies,  the
          health care industry and general market conditions.

     In addition,  in recent years the stock market has experienced  significant
price and volume fluctuations.  These fluctuations, which are often unrelated to
the operating  performance of specific companies,  have had a substantial effect
on the market price for many health care related technology  companies.  Factors
such as those cited above, as well as other factors that may be unrelated to our
operating performance may adversely affect the price of our common stock.

     The  application of the "penny stock" rules to our common stock may depress
the market for our stock.

     Trading of our common  stock may be subject to the penny  stock rules under
the Securities  Exchange Act of 1934, as amended,  unless an exemption from such
rules is available.  Broker-dealers  making a market in our common stock will be
required to provide disclosure to their customers regarding the risks associated
with our common stock,  the suitability for the customer of an investment in our
common stock,  the duties of the  broker-dealer  to the customer and information
regarding  bid  and ask  prices  for  our  common  stock,  and  the  amount  and
description of any  compensation the  broker-dealer  would receive in connection
with a  transaction  in our common  stock.  The  application  of these rules may
result in fewer  market  makers  making a market of our common stock and further
restrict the liquidity of our common stock.

     We do not  anticipate  paying any cash dividends on our common stock in the
foreseeable future.

     We have not had earnings, but if earnings were available, it is our general
policy to retain any earnings  for use in our  operation.  Therefore,  we do not
anticipate  paying any cash  dividends  on our common  stock in the  foreseeable
future.  Any payment of cash dividends on our common stock in the future will be
dependent  upon our  financial  condition,  results of  operations,  current and
anticipated  cash  requirements,  plans for expansion,  as well as other factors
that the Board of  Directors  deems  relevant.  We  anticipate  that our  future
financing agreements will prohibit the payment of common stock dividends without
the prior written consent of those providers.


                        FORWARD-LOOKING STATEMENTS

     This  Prospectus  and the  documents  incorporated  by reference  into this
Prospectus contain  forward-looking  statements,  which mean that they relate to
events or transactions that have not yet occurred, our expectations or estimates
for Medix's future operations,  our growth strategies or business plans or other
facts that have not yet occurred.  Such  statements can be identified by the use
of  forward-looking   terminology  such  as  "might,"  "may,"  "will,"  "could,"
"expect,"  "anticipate,"  "estimate,"  "likely," "believe," or "continue" or the
negative  thereof or other  variations  thereon or comparable  terminology.  The
following risk factors contain  discussions of important  factors that should be
considered   by   prospective   investors   for   their   potential   impact  on
forward-looking  statements  included in this  Prospectus  and in the  documents
incorporated by reference into this Prospectus.  These important factors,  among
others,  may cause actual  results to differ  materially  and adversely from the
results expressed or implied by the forward-looking statements.


                                   THE COMPANY

General

     Medix  Resources,  Inc.,  a  Colorado  corporation,  sold its  supplemental
staffing business, which operated under the tradenames "National Care Resources"
and  "TherAmerica" on February 19, 2000, and now principally  develops  software
for Internet-based communications and information management for medical service
providers, through its wholly-owned subsidiary, Cymedix Lynx Corporation.

     We acquired the Cymedix business in January of 1998.  Cymedix has developed
Internet-based communications and information management product, which we began
marketing to medical  professionals in select markets nationwide.  Growth of the
medical information  management marketplace is being driven by the need to share
significant  amounts of clinical  and patient  information  between  physicians,
their outpatient service providers,  hospitals,  insurance companies and managed
care  organizations.  This  market  is  one of the  fastest-growing  sectors  in
healthcare  today,  commanding  a projected  two-thirds  of health care  capital
investments.  The Cymedix(R)software contains patented elements that can be used
to develop secure medical communications products that make use of the Internet.
Using the Cymedix  software,  medical  professionals  can order,  prescribe  and
access medical  information from participating  insurance  companies and managed
care  organizations,  as well  as  from  any  participating  outpatient  service
provider, such as a laboratory,  radiology center, pharmacy or hospital. We will
provide the software at minimal  charges to  physicians  and  clinics,  and will
collect user fees whenever  these  products are used to provide  services on the
Internet.  The products'  relational database technology will provide physicians
with a permanent,  ongoing record of each patient's name, address,  insurance or
managed care affiliation,  referral status, medical history,  personalized notes
and an audit trail of past encounters. Physicians will be able to electronically
order  medical  procedures,  receive  and  store  test  results,  check  patient
eligibility,   make  medical  referrals,  request  authorizations,   and  report
financial  and  encounter  information  in a  cost-effective,  secure and timely
manner.

     Our  principal  executive  office is located at The Graybar  Building,  420
Lexington Ave., Suite 1830 New York, NY 10170, and its telephone number is (212)
697-2509.  Our principal  administrative  office is at 7100 East Belleview Ave.,
Greenwood Village, CO 80111, and its telephone number is (303) 741-2045. We also
have offices in California and Georgia.

Recent Developments

     The  introduction  of our next  generation  of  proprietary,  point-of-care
products,  Cymedix(R)III,  is  proceeding  with  our six  active  sponsors.  Our
improved  suite of software  products is based upon a robust and  device-neutral
architecture   that  leverages   proven   workstation,   handheld  and  wireless
technologies  and is being  installed  and tested for Pharmacy,  Laboratory  and
PlanConnect  services.  We continue to be in the  development  and testing phase
with each of our active  contracts,  and therefore  receive no revenue.  Revenue
will begin when we reach certain milestones under each contract and we enter the
production  phase of the contract.  The marketing and development of our Cymedix
suite of software  products is our sole business at this time, and a substantial
portion of our net operating  loss is due to such  efforts.  We are funding such
expenses  as  well  as our  administrative  expenses  through  the  sale  of our
securities. We have no significant debt financing available to us.

     During 2001, our Automated Design Concepts Division (ADC) ceased operations
in connection with our cost reduction program,  which had been brought on by our
inability to raise budgeted capital.  It was determined that the business of the
subsidiary  was not part of our core business  operations  and therefore did not
justify our continued  financial support.  In connection with the termination of
our  subsidiaries  operations  we took a write-off  of goodwill in the amount of
$443,000.  We also  determined  that our license of  proprietary  software  from
Zirmed.com had no value to us and had no more than a nominal market value.  As a
result,  we wrote-off the  unamortized  value of the related  intangible  asset,
which was  $668,000.  We had  acquired  ADC in early  2000 from an  officer  and
director of the Company for cash and stock valued at  $474,000.  He resigned his
positions with us on March 2, 2001.

     During  2001,  net cash  used in  operating  activities  was  approximately
$5,397,000.  During  the  year,  we  raised  approximately  $5,205,000  from the
exercise of options and  warrants,  and the  issuance  of common  stock,  net of
offering  expenses,  and debt. Since December 31, 2001 to June 30, 2002, we have
used  approximately   $2,298,000  in  our  operating   activities,   and  raised
approximately  $3,460,000  from the  exercise of options and  warrants,  and the
issuance of common stock and warrants,  net of offering  expenses,  and debt. We
had  approximately  $281,000  in cash as of June  30,  2002  with a net  working
capital deficit of approximately $1,212,000. We have been delinquent,  from time
to time,  in the  payment of our  current  obligations,  including  payments  of
withholding  and  other  tax   obligations.   We  continue  in  discussions  and
negotiations with institutional  sources regarding debt and equity financings to
fund our operations and to permit us to remove the "going concern" qualification
in our  auditor's  report in connection  with the audit of our annual  financial
statements.  There can be no assurance that additional investments or financings
will be  available  to us as needed.  Failure to obtain such capital on a timely
basis  could  result in lost  business  opportunities,  the sale of the  Cymedix
business at a distressed price or our financial failure.

     We executed an Amended and  Restated  Common  Stock  Purchase  Warrant with
WellPoint  Pharmacy  Management,  dated  February 18, 2002, to  restructure  our
obligations to issue warrants to WellPoint. Under that Warrant, we are obligated
to issue up to 7,000,000  shares of our common stock at exercise prices of $0.30
per share for  3,000,000,  $0.50 per share for  3,000,000  shares  and $1.75 per
share for 1,000,000 shares, if various performance related vesting  requirements
are satisfied by WellPoint.  Currently, WellPoint has satisfied certain of these
requirements  giving  WellPoint  the right to purchase  1,850,000  shares of our
common  stock at $0.30 per  share  have been  earned by  WellPoint.  WellPoint's
rights to purchase our shares under the Warrant expire on September 8, 2004. The
Warrant  grants  to  WellPoint  certain  registration  rights to  require  us to
register  with the SEC the shares  issued to WellPoint for resale to the public.
In the Warrant,  WellPoint  has agreed to restrict  sales to the public of these
shares  during the first year after they have been issued to 200,000  shares per
month  and  100,000  shares  in any five  trading  days.  The  Warrant  contains
anti-dilution  provisions  providing  that  the  number  of  shares  that may be
purchased   by   WellPoint   under  the   Warrant  my  be  adjusted  in  certain
circumstances.

     We entered into a secured convertible loan agreement with WellPoint,  dated
February  19,  2002,  pursuant to which we borrowed  $1,000,000  from  WellPoint
Health  Networks  Inc.  The loan becomes  payable on February  19, 2003,  if not
converted  into our common stock.  The loan earns annual  interest at a floating
rate of 300 basis points over prime, as it is adjusted from time to time,  which
is also payable at maturity and may be converted  into common stock.  Conversion
into common stock is at the option of either  WellPoint or Medix at a contingent
conversion  price. The conversion price will be either (i) at the price at which
additional shares are sold to other private placement investors if Medix obtains
written commitments for at least an additional $4,000,000 of equity by the close
of business on September 30, 2002, from persons not affiliates of WellPoint, and
if such sales are closed by the  maturity  date of the loan,  or (ii) at a price
equal to 80% of the  then-current  Fair Market Value (as defined below) if Medix
is unable to obtain a written commitment for the additional equity investment by
the close of business on  September  30, 2002 or close the sales by the maturity
date. For this purpose,  "Fair Market Value" shall be the average  closing price
of Medix common stock for the twenty trading days ending on the day prior to the
day of the conversion.  The loan is secured by the grant of a security  interest
in all Medix's  intellectual  property,  including  its patent,  copyrights  and
trademarks.  While Medix can cure a default in the  repayment of the loan at the
fixed maturity date by the forced  conversion of the loan into its common stock,
a cross default, breach of representation or warranty, and bankruptcy or similar
event  of  default  will  trigger  the  foreclosure  provision  of the  security
agreement.

     On May 15, 2002,  we completed a private  placement of our  securities  for
$1,381,000.  In connection therewith,  we are issuing 3,452,500 shares of common
stock and  warrants to purchase a equal  number of shares of common stock at the
exercise  price of $0.50 per share.  We are  obligated  to register all of those
shares with the SEC for resale by their holders as soon as reasonably possible.


                                   EQUITY LINE FINANCING

Agreement

     We have  entered  into an Equity  Line of  Credit  Agreement  with  Cornell
Capital  Partners,  L.P.  ("Cornell"),  and Dutchess Private Equities Fund, L.P.
("Dutchess"),  dated as of June 12, 2001. Under the agreement, the two providers
have  committed  to  advance to us funds in an amount of up to  $10,000,000,  as
requested by us, over a 24-month  period in return for common stock issued by us
to the providers.  As of July 24, 2002, we had received  $2,681,099 in advances,
from which offering expenses of $198,511 were paid, under the financing, and had
issued to the  providers  4,703,237  shares of our common stock  relating to the
advances  and an  additional  542,847  shares  to their  affiliates  as fees for
arranging the equity line  facility.  The shares  issued  pursuant to the equity
line advances to date have been priced from $0.41 to $0.77 per share.

     The  amount  that may be  advanced  at any time  under the  equity  line is
limited as follows (which conditions may be waived by the providers):

     o    There must be thirteen  stock  market  trading days between any two of
          our requests for advances.
     o    We can only request an advance if the volume weighted average price of
          the common stock, as reported by Bloomberg L.P. for the day before our
          request, is equal to or greater than the volume weighted average price
          as reported by Bloomberg L.P. for the 22 trading days before we make a
          request.
     o    We will not be able to receive an advance  amount that is greater than
          175% of the  average  daily  volume of our  common  stock  over the 40
          trading days prior to our advance  request  multiplied by the purchase
          price (calculated as provided in the next sentence).

     The purchase price of our common stock issued in each advance will be equal
to 91% of the three lowest daily volume  weighted  average  prices during the 22
trading days before we make a request for an advance.

Registration Rights

     We have agreed to maintain an effective registration statement for the sale
of the shares issued to the providers of our equity line financing, as described
above.  If, at any time,  the number of shares  available  under a  registration
statement is  insufficient to cover all securities  issued to the providers,  we
have agreed to use our best efforts to cause an  amendment  or new  registration
statement  containing those shares to be declared effective.  Our agreement with
the providers of our equity line financing contains mutual  indemnities  against
loses,  costs and expenses arising out of the violation of by the other party of
state and Federal securities laws.  Insofar as  indemnification  for liabilities
under the  Securities  Act of 1933,  as  amended,  may be  permitted  under such
agreement,  we have been informed that in the opinion of the U.S. Securities and
Exchange Commission,  such indemnification is against public policy as expressed
in the  Securities  Act and is therefore  unenforceable.  Our  agreements  as to
registration rights are only with the providers of our equity line financing and
we have no  obligations  to assist or  indemnify  any other holder of the shares
sold by them or to any underwriter designated by such holders.

     Currently,  4,796,763  shares are  registered  for sale by the providers in
connection  with future draws.  If additional  shares are to be issued under the
equity line of credit,  they would have to be registered with the SEC and listed
on the AMEX.  Listing of  additional  shares on the AMEX would require a vote of
our shareholders under the AMEX rules the limit the number of shares that can be
issued in below market transactions.

     Since April 30,  2002,  we have not been able to draw on the equity line of
credit  because  the SEC has not  declared  a  post-effective  amendment  to the
registration statement registering these shares effective.  The SEC has informed
us that it has "serious  concerns"  about  certain  aspects of the  compensation
structure  discussed  in the  following  paragraph,  and  will  not  permit  the
post-effective  amendment to the registration statement to become effective, and
therefore  further draws under the equity line of credit,  until those  concerns
are resolved.

Compensation

     We are selling our shares to the providers of our equity line  financing at
a 9% discount  from the market price as described  above.  Yorkville  Advisors's
Management,  LLC, an affiliate of Cornell, has been and will be paid by us 2.31%
of each amount advanced to us under the equity line financing. Dutchess Advisors
Limited, an affiliate of Dutchess, has been and will be paid by us 4.69% of each
amount advanced to us under the equity line financing. Through July 24, 2002, we
have  paid an  aggregate  of  $175,511  in such  fees.  Furthermore,  for  their
assistance  in arranging our equity line  facility,  we have issued to Yorkville
Advisors and Dutchess Advisors 179,140 shares and 363,707 shares,  respectively,
of  our  common   stock,   which  was  also   registered   for  sale  under  the
above-described  registration statement. In addition,  through July 24, 2002, we
have paid $15,000,  in the aggregate,  to counsels to Cornell and Dutchess,  and
paid  $8,000  for  escrow  fees and  other  expenses  in  connection  with  this
transaction.

Potential Dilution

     We have made 17 draws under the equity line since August 15, 2001, received
$2,681,099 in advances and issued 4,703,237 shares of common stock to the equity
line  providers.  The issue price of that stock has been between $0.41 and $0.77
during a period  when the market  prices on the draw dates has ranged from $0.50
to $0.94.

     The following table is intended to indicate the future impact of our equity
line on the number of shares of our common stock outstanding,  assuming the draw
down of all the remaining  availability  under the equity line, all at one time,
for hypothetical variations in the price of our common stock. The numbers in the
table are  hypothetical  and it is highly unlikely that we will draw down all of
the amount available under the equity line at one time. As of June 18, 2002, the
closing  price of our  common  stock on the AMEX was  $0.38 per  share,  and the
number of shares of our common stock outstanding was 62,923,624 shares.

     Under our equity line of credit,  the  purchase  price of our common  stock
issued to the equity line providers is  contractually  set at 91% of the average
of the three lowest daily volume weighted average prices ("VWAPs") during the 22
trading days before a draw is made.  On July 24, 2002,  the average of the three
lowest VWAPs for the prior 22-trading day period was $0.37. On that date, we had
$7,318,901  available to be drawn down under the equity line.  In the  following
table we present the number of shares that could be issued,  and the issue price
thereof, in six different hypothetical  situations,  if the average of the three
lowest  VWAPs for the  pricing of the shares to be issued in an equity line draw
down were 25%, 50% and 75% above and below that average on July 24, 2002.

----------------------------------------------------------------------------
    Assumed        Price to     Number of shares that  Shares shown in the
  average of      equity line     could be issued if     prior column are
 three lowest      providers          remaining         percentage of the
    VWAPs                          availability was     assumed resulting
                                drawn at the price in   outstanding shares
                                   the prior column
----------------------------------------------------------------------------
    $0.0925         $0.0842           86,948,631              58.02%
----------------------------------------------------------------------------
    $0.1850         $0.1684           43,474,315              40.86%
----------------------------------------------------------------------------
    $0.2775         $0.2525           28,982,877              31.54%
----------------------------------------------------------------------------
    $0.4625         $0.4209           17,389,726              21.65%
----------------------------------------------------------------------------
    $0.5550         $0.5051           14,491,438              18.72%
----------------------------------------------------------------------------
    $0.6475         $0.5892           12,421,233              16.49%
----------------------------------------------------------------------------


                                 USE OF PROCEEDS

     The net  proceeds  from the sale of shares  will be received by the selling
shareholders.  Medix will not receive any of the  proceeds  from any sale of the
shares by the selling  shareholders.  However,  Medix will  receive the proceeds
from the  exercise  of warrants  and  options to purchase  the shares to be sold
hereunder.  If all  related  warrants  and options  are  exercised,  Medix would
receive  proceeds of $234,625.  However,  rights to exchange the equity value of
some  warrants and options in the exercise of other  warrants and options  could
reduce the amount  received in cash upon the  exercise  the warrants and options
referred  to in this  Prospectus.  Any  such  proceeds  will be used as  working
capital.


                              SELLING SHAREHOLDERS

     The table below sets forth information as of July 24, 2002, with respect to
the selling  shareholders,  including names,  holdings of shares of common stock
prior to the offering of the shares, the number of shares being offered for each
account,  and the number and percentage of shares of common stock to be owned by
the selling shareholders  immediately following the sale of the shares, assuming
all of the offered  shares are sold.  We have been  informed that the voting and
investment  control of Nais  Corporation  is exercised by its sole  shareholder,
Mrs.  Pauline  Winter,  and its  board  of  directors,  Mrs.  Winter,  Mr.  Eric
Ehrenhaus, Dr. Michael Ehrenhaus and Ms. Fawn Spirgel.

                                Shares of
                                 Common
                                  Stock       Shares of
                               Beneficially    Common       Shares of Common
                                  Owned        Stock         Stock to be
                               Before the      Being       Beneficially Owned
             Name               Offering       Offered     After the Offering
-------------------------------------------------------------------------------
                                                           Number    Percentage
                                                           --------------------
  Michael I. Ruxin              243,750        243,750           0        0
  Nais Corporation              250,000         90,000     160,000        *
  Lyle B. Stewart               200,000         75,000     125,000        *
  Fritz & Miller, P.C.           15,035          9,568       5,467        *
  Shapiro Forman Allen &         30,800         19,600      11,200        *
 Miller LLP
  Guli R. Rajani                 30,555         19,444      11,111        *
  Nicole S. Rajani               30,555         19,444      11,111        *
  Ajay G. Rajani                 30,555         19,444      11,111        *
      Total                      831,250       496,250
_________
*less than 1%

Relationship Between Medix and the Selling Shareholders

     The selling  shareholders  have or will  acquire the shares of common stock
indicated  above upon the  exercise of warrants or options  issued for  services
rendered or in settlement of  litigation.  None of the persons  listed above are
affiliates  or  controlled  by  affiliates  of the  Company.  We have a separate
contractual  obligation  to file this  registration  with certain of the selling
shareholders.

     All of the other selling  shareholders,  other than Mr.  Stewart,  received
their shares as a result of the settlement of three litigations with us, Michael
I. Ruxin v. Cymedix Lynx Corporation,  and Medix Resources, Inc., Guli R. Rajani
v. Medix  Resources,  Inc., and Yecheskel Munk and the Nais Corporation v. Medix
Resources,  Inc.  f/k/a  International  Nursing  Services,  Inc.  They  were all
discussed  in our 2000 Form  10-KSB.  In the  first  two  cases  the  settlement
involved  issuing  warrants to the plaintiffs  giving them the right to purchase
243,750 and 137,500  shares,  respectively,  of our common stock at the exercise
price  of  $0.50  per  share.  In  the  third  litigation,  the  plaintiff  Nais
Corporation  was  issued  90,000  shares of our common  stock in the  negotiated
settlement of the matter.  In each  settlement the case against us was dismissed
with prejudice. Mr. Rajani has directed a portion of the warrants he received in
the settlement to his wife and son and to the counsel who represented him in his
litigation against us. 50,000 shares covered by Mr. Rajani's settlement warrants
were registered in an earlier  registration  statement declared effective by the
SEC.

     Mr. Stewart,  our outside legal counsel,  has received a compensatory grant
of options  under our 1999 Stock Option Plan  covering the shares  registered in
his name. They are exercisable at $0.92 per share.


                        DESCRIPTION OF SECURITIES

     Our authorized  capital consists of 100,000,000 shares of common stock, par
value $.001 per share,  and 2,500,000  shares of preferred stock. As of July 24,
2002, we had  outstanding  62,923,624  shares of common  stock,  1 share of 1996
Preferred  Stock,  50 shares of 1999 Series B Preferred  Stock and 100 shares of
1999 Series C Preferred  Stock.  As of such date,  our common  stock was held of
record by  approximately  430 persons and  beneficially  owned by  approximately
9,000 persons.

Common Stock

     Each  share of common  stock is  entitled  to one vote at all  meetings  of
shareholders.  Shareholders  are not permitted to cumulate votes in the election
of directors.  Currently,  the Board of Directors consists of six directors, who
serve for staggered terms of three years, with at least two directors elected at
every  annual  meeting.  All shares of common stock are equal to each other with
respect to  liquidation  rights and  dividend  rights.  There are no  preemptive
rights to purchase any  additional  common stock.  In the event of  liquidation,
dissolution or winding up of Medix, holders of the common stock will be entitled
to receive on a pro rata basis all assets of Medix remaining after  satisfaction
of all  liabilities  and preferences of the  outstanding  preferred  stock.  The
outstanding  shares of common stock and the shares of common stock issuable upon
conversion or exercise of derivative  securities are or will be, as the case may
be, duly and validly issued, fully paid and non-assessable.

Transfer Agent and Registrar

     We have retained  Computershare  Trust Company,  Inc., 350 Indiana  Street,
Suite 800, Golden, Colorado 80401, as Transfer Agent and Registrar,  for the our
common stock, at telephone number (303) 262-0600.

                              PLAN OF DISTRIBUTION

     The selling shareholders and any of their pledgees,  donees,  assignees and
successors-in-interest  may, from time to time,  sell any or all of their shares
of Common Stock on any stock exchange,  market or trading  facility on which the
shares are traded. These sales may be at fixed or negotiated prices. The selling
shareholders  may use any one or more  of the  following  methods  when  selling
shares:

     o    ordinary   brokerage   transactions  and  transactions  in  which  the
          broker-dealer solicits purchasers;

     o    block  trades  in which the  broker-dealer  will  attempt  to sell the
          shares as agent but may  position and resell a portion of the block as
          principal to facilitate the transaction;

     o    purchases  by  a   broker-dealer   as  principal  and  resale  by  the
          broker-dealer for its account;

     o    an  exchange   distribution  in  accordance  with  the  rules  of  the
          applicable exchange;

     o    privately negotiated transactions;

     o    short sales;

     o    broker-dealers  may  agree  with the  selling  shareholders  to sell a
          specified number of such shares at a stipulated price per share;

     o    a combination of any such methods of sale; and

     o    any other method permitted pursuant to applicable law.

     The  selling  shareholders  may also sell  shares  under Rule 144 under the
Securities Act, if available, rather than under this prospectus.

     The selling  shareholders  may also engage in short sales  against the box,
puts  and  calls  and  other  transactions  in  securities  of  the  Company  or
derivatives  of Company  securities and may sell or deliver shares in connection
with these  trades.  The selling  shareholders  may pledge their shares to their
brokers  under  the  margin  provisions  of  customer  agreements.  If a selling
shareholder  defaults on a margin loan, the broker may, from time to time, offer
and sell the pledged shares.  The selling  shareholders have advised the Company
that they have not entered into any agreements,  understandings  or arrangements
with any underwriters or broker-dealers regarding the sale of their shares other
than ordinary  course  brokerage  arrangements,  nor is there an  underwriter or
coordinating broker acting in connection with the proposed sale of shares by the
selling shareholders.

     Broker-dealers  engaged by the selling  shareholders  may arrange for other
brokers-dealers to participate in sales.  Broker-dealers may receive commissions
or discounts from the selling  shareholders  (or, if any  broker-dealer  acts as
agent  for the  purchaser  of  shares,  from the  purchaser)  in  amounts  to be
negotiated.  The  selling  shareholders  do not  expect  these  commissions  and
discounts to exceed what is customary in the types of transactions involved.

     Selling  shareholders and any broker-dealers or agents that are involved in
selling the shares may be deemed to be "underwriters"  within the meaning of the
Securities Act in connection  with such sales.  In such event,  any  commissions
received  by such  broker-dealers  or agents and any profit on the resale of the
shares  purchased  by them  may be  deemed  to be  underwriting  commissions  or
discounts under the Securities Act.

     The  Company  is  required  to pay all fees and  expenses  incident  to the
registration  of the  shares,  including  fees and  disbursements  of counsel to
certain of the selling shareholders.  Otherwise,  all discounts,  commissions or
fees  incurred in connection  with the sale of the common stock  offered  hereby
will be paid by the selling  shareholders.  The Company has agreed to  indemnify
certain  selling  shareholders  against  certain  losses,  claims,  damages  and
liabilities, including liabilities under the Securities Act.

     Upon the Company being notified by a selling  shareholder that any material
arrangement  has been entered into with a  broker-dealer  for the sale of shares
through a block trade,  special  offering,  exchange  distribution  or secondary
distribution  or a  purchase  by a  broker  or  dealer,  a  supplement  to  this
prospectus  will be  filed,  if  required,  pursuant  to Rule  424(b)  under the
Securities Act,  disclosing (i) the name of each such selling shareholder and of
the participating  broker-dealer(s),  (ii) the number of shares involved,  (iii)
the price at which such shares were sold, (iv) the commissions paid or discounts
or concessions allowed to such broker-dealer(s), where applicable, (v) that such
broker-dealer(s) did not conduct any investigation to verify the information set
out or  incorporated  by  reference  in this  prospectus,  and (vi) other  facts
material to the transaction.

     In  order  to  comply  with  the  securities  laws of  certain  states,  if
applicable,  the shares will be sold in such  jurisdictions,  if required,  only
through  registered  or licensed  brokers or dealers.  In  addition,  in certain
states the shares may not be sold  unless  the shares  have been  registered  or
qualified  for  sale  in  such  state  or  an  exemption  from  registration  or
qualification is available and complied with.

     The Company has advised the selling shareholders that the anti-manipulative
provisions of Regulation M promulgated under the Exchange Act may apply to their
sales of the shares offered hereby.


                    INDEMNIFICATION OF OFFICERS AND DIRECTORS

     Article 109 of the Colorado  Business  Corporation  Act generally  provides
that Medix may indemnify its directors,  officers,  employees and agents against
liabilities  in  any  action,  suit  or  proceeding  whether  civil,   criminal,
administrative or investigative and whether formal or informal (a "Proceeding"),
by reason of being or having been a director,  officer,  employee,  fiduciary or
agent of Medix, if such person acted in good faith and reasonably  believed that
his conduct,  in his official capacity,  was in the best interests of Medix (or,
with  respect  to  employee  benefit  plans,  was in the best  interests  of the
participants of the plan),  and in all other cases that his conduct was at least
not opposed to Medix's best interests. In the case of a criminal proceeding, the
director,  officer,  employee  or agent  must  have had no  reasonable  cause to
believe  that his  conduct  was  unlawful.  Under  Colorado  Law,  Medix may not
indemnify a director, officer, employee or agent in connection with a proceeding
by or in the right of Medix if the director is adjudged liable to Medix, or in a
proceeding in which the directors,  officer employee or agent is adjudged liable
for an improper personal benefit.

     Our  Articles  of  Incorporation   provide  that  we  shall  indemnify  its
directors,  and  officers,  employees and agents to the extent and in the manner
permitted by the  provisions  of the laws of the State of  Colorado,  as amended
from time to time,  subject to any  permissible  expansion or limitation of such
indemnification,  as  may be  set  forth  in  any  shareholders'  or  directors'
resolution or by contract.

     Insofar as  indemnification  for  liabilities  under the  Securities Act of
1933, as amended (the "Securities Act"), may be permitted to directors, officers
or persons  controlling  Medix pursuant to the foregoing  provisions,  Medix has
been informed that in the opinion of the  Commission,  such  indemnification  is
against  public  policy as  expressed  in the  Securities  Act and is  therefore
unenforceable.


                              AVAILABLE INFORMATION

     We are a  reporting  company  and file our  annual,  quarterly  and current
reports,  proxy  material and other  information  with the SEC.  Reports,  proxy
statements and other information  concerning Medix filed with the Commission may
be inspected at the Public  Reference  Room  maintained by the Commission at its
office, 450 Fifth Street, N.W., Washington,  D.C. 20549. Copies of such material
can be obtained from the Public  Reference  Room of the  Commission at 450 Fifth
Street, N.W., Washington, D.C. 20549, at prescribed rates. The public may obtain
information  about the Public reference room in Washington,  D.C. by calling the
SEC at  1-800-SEC-0330.  Our SEC filings are also available at the SEC's Website
at "http://www.sec.gov".

     We have filed a  registration  statement  under the  Securities  Act,  with
respect to the securities  offered pursuant to this Prospectus.  This Prospectus
does not contain all of the information set forth in the registration statement,
certain parts of which are omitted in accordance  with the rules and regulations
of  the  Commission.   For  further  information,   reference  is  made  to  the
registration  statement and the exhibits  filed as a part thereof,  which may be
found at the locations and Website referred to above.


                INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

     The SEC allows us to  "incorporate by reference"  information  that we file
with them,  which means that we can  disclose  important  information  to you by
referring  you  to  the  documents   filed  with  the  SEC  that  contains  that
information.  The information  incorporated by reference is an important part of
this  Prospectus,  and it is  important  that you review it before  making  your
investment  decision.  We hereby  incorporate by reference the documents  listed
below:

     (a)  a copy of our  Annual  Report on Form 10-K for the  fiscal  year ended
          December 31, 2001, filed with the SEC on April 1, 2002;

     (b)  a copy of our Form 10-K/A, filed with the SEC on April 5, 2002;

     (c)  a copy of our Form 10-K/A, filed with the SEC on April 15, 2002;

     (d)  a copy of our Annual  Report on Form  10-K/A for the fiscal year ended
          December  31, 2001,  as amended,  and as filed with the SEC on May 24,
          2002;

     (e)  a copy of our  Quarterly  Report on Form 10-Q for the  fiscal  quarter
          ended March 31, 2002, as filed with the SEC on May 15, 2002;

     (f)  copies of the our Forms 8-K,  filed with the SEC on January 18,  March
          4, and March 25, April 12, May 24, June 4, June 14 (2 Forms 8-K),  and
          June 26, 2002.

     We are  delivering  with this  Prospectus  copies of the most  recent  Form
10-K/A and Form 10-Q referred to above.  Any  statement  contained in a document
incorporated or deemed to be incorporated  by reference in this  Prospectus,  or
made herein,  shall be deemed to be modified or superseded  for purposes of this
Prospectus  to  the  extent  that  a  statement   contained  herein  or  in  any
subsequently  filed  document,  which also is or is deemed to be incorporated by
reference  herein,  modifies or  supersedes  such  statement.  Any  statement so
modified or superseded shall not be deemed, except as so modified or superceded,
to constitute a part of this Prospectus.

     All other documents filed by the Company pursuant to Sections 13(a), 13(c),
14 and 15(d) of the Securities  Exchange Act of 1934, as amended,  subsequent to
the  date of this  Prospectus  and  prior  to the  termination  of the  Offering
pursuant to this Prospectus  shall be deemed to be incorporated by reference and
to be a part of this Prospectus from the date of filing of such documents.

     We will provide  without  charge to each person,  including any  beneficial
owner,  to whom a copy of this  Prospectus  is  delivered,  upon oral or written
request of any such person,  a copy of any or all of the documents  incorporated
herein by  reference,  other than the  exhibits to such  documents  (unless such
exhibits are  specifically  incorporated by reference into the information  that
this Prospectus incorporates). Requests should be directed to Investor Relations
Department,  Medix  Resources,  Inc.,  7100  E.  Belleview  Avenue,  Suite  301,
Greenwood Village, Colorado 80111, telephone (303) 741-2045.


                                  LEGAL MATTERS

     The  validity of the shares  offered  hereby is being passed upon for us by
Lyle B. Stewart, P.C. Lyle B. Stewart, P.C. has been granted options to purchase
25,000 shares of Medix common stock at an exercise price of $0.26 per share, and
Mr.  Stewart,  individually,  has been granted  options to purchase  100,000 and
75,000  shares of Medix common  stock at exercise  prices of $3.38 and $0.92 per
share, respectively.


                                     EXPERTS

     The consolidated financial statements of Medix as of December 31, 2001, and
for each of the three years in the period ended  December 31, 2001  appearing in
our 2001 Form 10-K have been audited by Ehrhardt  Keefe  Steiner & Hottman P.C.,
independent auditors, as stated in their report appearing therein, and have been
incorporated  herein by reference in reliance upon the report of such firm given
upon their authority as experts in accounting and auditing.